Opko Health Inc. (OPK)
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago.
OPKO Health Q2 Earnings Call Highlights
OPKO Health NASDAQ: OPK reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPKO Health rides on RAYALDEE strength, partnerships and restructuring gains, but reliance on a single drug keeps risk in focus for investors.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.
Critical Analysis: OPKO Health (NASDAQ:OPK) vs. Hypertension Diagnostics (OTCMKTS:HDII)
OPKO Health (NASDAQ: OPK - Get Free Report) and Hypertension Diagnostics (OTCMKTS:HDII - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares OPKO Health
